New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Jose Baselga
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071214_jose_baselga.mp3]
